• Miguel Guimarães, Ana Gonçalves, Ivone Pascoal, and João Moura.
• Chest. 2014 Mar 1;145(3 Suppl):10A.

Session TitleAsthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Despite optimal treatment, some asthmatic remain symptomatic with frequent exacerbations and persistent obstruction of the airways. Tiotropium addition is associated with reduced risk of exacerbations and sustained bronchodilatation(BD). Objectives: Characterization of asthmatic patients with optimized treatment and treated with tiotropium. Assess the role of tiotropium in symptomatic control and lung function.MethodsRetrospective cohort study with asthmatic patients observed during 2012 and treated with tiotropium for at least 6 months. Data Collected: Demographic, anthropometric; Lung Function tests; co-morbidities and disease control.Results41 patients (32-78% women) which correspond to 10% of all patients followed. Mean age: 53,92 years(min:23;max:77) and mean BMI:30,31 Kg/m2 . 4(9,8%) are smokers, 19(46,1%) with rhinitis, 5(12,2%) sinusitis, 16(39%) GERD, 10(24,4%) depression and 19(46,3%) atopic. Inicial asthma severity: 1(2,4%) mild persistent; 16(39%) moderate persistent; 24(58,5%) severe persistent. Before triotropium: 16(39%) partly controlled; 25(61%) uncontrolled. After triotropium: 22(53,7%) controlled; 13(31,7%) partly controlled and 6(14,6%) uncontrolled. Before tiotropium the mean FEV1 preBD was 1,55L(61,76%) and postBD of 1,7 L(65,5%). After tiotropium mean FEV1 preBD was 1,64 L(68,65%) and postBD of 1,74 L(73,19%). There was an increase in FEV1 in the majority (68.3%, n = 28), with an average increase of 90 ml in preBD FEV1.ConclusionsMost patients have co-morbidities and high BMI. In uncontrolled asthmatics despite optimal therapy, it was identified a better disease control and an increase in FEV1 with the addition of tiotropium.Clinical ImplicationsSome asthmatic remain symptomatic with frequent exacerbations despite optimal treatment .Tiotropium addition may be an option in this patients.DisclosureThe following authors have nothing to disclose: Ana Gonçalves, Ricardo Lima, Ivone Pascoal, João Moura, Miguel Guimarães, Raquel Duarte, Aurora CarvalhoNo Product/Research Disclosure Information.

10 keywords...

hide…